Teva Pharmaceutical Industries (NYSE:TEVA) Shares Gap Up – Should You Buy?

Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s share price gapped up before the market opened on Tuesday . The stock had previously closed at $16.25, but opened at $17.15. Teva Pharmaceutical Industries shares last traded at $16.96, with a volume of 3,659,756 shares traded.

Wall Street Analyst Weigh In

TEVA has been the topic of a number of recent research reports. Barclays cut their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, January 30th. UBS Group lowered their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Piper Sandler boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. Finally, StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $23.57.

Teva Pharmaceutical Industries Price Performance

The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The stock has a market capitalization of $19.28 billion, a price-to-earnings ratio of -11.73, a P/E/G ratio of 1.34 and a beta of 0.71. The company has a 50-day moving average of $19.91 and a 200-day moving average of $18.49.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, equities research analysts expect that Teva Pharmaceutical Industries Limited will post 2.62 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the sale, the director now directly owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.55% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Creative Planning grew its stake in shares of Teva Pharmaceutical Industries by 4.5% during the 3rd quarter. Creative Planning now owns 42,815 shares of the company’s stock valued at $772,000 after buying an additional 1,863 shares during the period. Blue Trust Inc. grew its stake in shares of Teva Pharmaceutical Industries by 40.1% during the 3rd quarter. Blue Trust Inc. now owns 14,619 shares of the company’s stock valued at $263,000 after buying an additional 4,185 shares during the period. Raymond James & Associates grew its stake in shares of Teva Pharmaceutical Industries by 25.1% during the 3rd quarter. Raymond James & Associates now owns 1,020,719 shares of the company’s stock valued at $18,393,000 after buying an additional 204,775 shares during the period. Sequoia Financial Advisors LLC grew its stake in shares of Teva Pharmaceutical Industries by 0.7% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock valued at $2,025,000 after buying an additional 805 shares during the period. Finally, Signaturefd LLC grew its stake in shares of Teva Pharmaceutical Industries by 16.9% during the 3rd quarter. Signaturefd LLC now owns 7,583 shares of the company’s stock valued at $137,000 after buying an additional 1,094 shares during the period. 54.05% of the stock is owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.